BEDFORD, Mass., Nov. 11, 2004 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of women's diagnostic imaging systems and state-of- the-art digital imaging systems, today announced it has received the Frost & Sullivan 2004 Technology Leadership of the Year Award in the field of women's health. The award recognizes Hologic for its work in the detection of breast cancer through tomosynthesis, a new investigational imaging technology.
Tomosynthesis is a 3-D imaging technology that involves the acquisition of multiple images of a stationary compressed breast from different angles during a short scan. Tomosynthesis is similar to CT, but unlike CT scans which commonly use 360 degree revolutions with less than hundred slices, tomosynthesis uses a smaller, selected number of angles with a detector with over 3,000 lines covering the complete breast. Tomosynthesis is also simpler to implement than CT and requires only modest modifications to existing mammography systems, whereas CT requires large complex scanners.
"We are very pleased to receive this award that formally recognizes Hologic as a technology leader in developing innovative imaging systems targeted at improving women's health," said Jack Cumming, Hologic's Chairman and CEO. "Breast tomosynthesis is an enabling technology we believe holds great promise in the early detection of breast cancer. It is our expectation digital breast tomosynthesis will reduce the recall rate of patients as it reduces the uncertainty arising from tissue overlap. In addition, the biopsy rate should also be decreased, as there is a noticeable improvement in visualization of breast tissue, particularly in women with dense breasts. All of us at Hologic remain committed to bringing this powerful tool to market in the fight against breast cancer."
Hologic first demonstrated tomosynthesis with patient images and a prototype system as an add-on to its Selenia full field digital mammography system at the Radiological Society of North America meeting in Chicago in November 2003. Clinical trials began in the summer of 2004 at major university research sites in the U.S.
"Tomosynthesis has the potential to revolutionize the practice of mammography by providing superior breast cancer detection with no additional radiation exposure and with improved patient comfort compared to conventional mammography," said Michael Valenti, Frost & Sullivan industry analyst. "Tomosynthesis shows promise for all three major applications of mammography: screening, diagnostic, and interventional. The technology is expected to provide superior detection of small occult lesions that may be missed by current mammography systems, and give radiologists increased confidence in their diagnoses."
Hologic Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to- digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications. For more information visit http://www.hologic.com/.
About Frost and Sullivan
Frost & Sullivan is an international marketing consulting firm. The Frost & Sullivan Technology Leadership of the Year Award recognizes technology developments that are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. Founded in 1961, Frost & Sullivan is recognized as a global marketing research and solution leader, with offices located worldwide: Silicon Valley, New York, Texas, London, Paris, Frankfurt, Beijing, Tokyo, Singapore, and Mumbai. For further information contact http://www.frost.com/.
Forward Looking Disclaimer
Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements by Frost & Sullivan and Hologic regarding the expected benefits from the tomosynthesis imaging technology. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Hologic cannot assure that it will be able to complete the development of its tomosynthesis system on a timely basis, if at all, or that once developed, the system will perform as anticipated or be commercially successful. Factors that could cause actual results to materially differ include, without limitation, uncertainties inherent in the development of new products and technologies and the enhancement of existing products, including technical, manufacturing and regulatory risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the risk that technical innovations could render products marketed or under development by Hologic obsolete; and competition with other products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.
Contact: Glenn P. Muir Frances Crecco Executive Vice President & CFO Director, Investor Relations Hologic, Inc. Hologic, Inc. (781) 999-7300 (781) 999-7377
SOURCE: Hologic, Inc.
CONTACT: Glenn P. Muir, Executive Vice President & CFO, +1-781-999-7300,
or Frances Crecco, Director, Investor Relations, +1-781-999-7377 both of